News

What’s Happening With Amgen Stock?
Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase over an ...
In the wake of Amgen Inc.'s (NASDAQ:AMGN) latest US$6.5b market cap drop, institutional owners may be forced to take severe actions
To get a sense of who is truly in control of Amgen Inc. (NASDAQ:AMGN), it is important to understand the ownership structure of the business. The group holding the most number of shares in the company ...
Fierce Biotech1d
Amgen rolls out phase 3 dosing plan for lead obesity candidate after midstage trial sees high discontinuation, vomiting rates
While Amgen’s monthly obesity candidate MariTide helped patients lose significant amounts of weight in a phase 2 study, ...
Where Amgen Stands With Analysts
Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether ...
STAT1d
Amgen’s obesity drug led to high discontinuation rates in mid-stage trial, as company plans to adjust dosing
Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a ...
BioPharma Dive1d
New Amgen obesity drug data disappoint Wall Street
Full Phase 2 study results showed side effects that led people to stop treatment with MariTide, as well as weight loss ...
Here's Why Amgen (AMGN) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Dallas Goedert talks all things Eagles after winning Super Bowl LIX
Eagles tight end Dallas Goedert stops by to talk all things Eagles, another year of TEU and his partnership with Amgen.